Canavan disease is caused by ASPA mutations that diminish brain aspartoacylase activity, and it is characterized by excessive brain storage of the aspartoacylase substrate, N-acetyl-l-aspartate (NAA), and by astroglial and intramyelinic vacuolation. Astroglia and the arachnoid mater express sodium-dependent dicarboxylate transporter (NaDC3), encoded by SLC13A3, a sodium-coupled transporter for NAA and other dicarboxylates. Constitutive Slc13a3 deletion in aspartoacylase-deficient Canavan disease mice prevents brain NAA overaccumulation, ataxia, and brain vacuolation. ANN NEUROL 2021;90:845-850.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549923 | PMC |
| http://dx.doi.org/10.1002/ana.26211 | DOI Listing |
Publication Analysis
Top Keywords
canavan disease
12
sodium-dependent dicarboxylate
8
dicarboxylate transporter
8
disease mice
8
ablating transporter
4
transporter sodium-dependent
4
transporter prevents
4
prevents leukodystrophy
4
leukodystrophy canavan
4
mice canavan
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!